Skip to content

Efficacy of freeze in treatment of cervical erosion

Combined pharmaco and Cryotherapy compared with only pharmacotherapy in symptomatic chronic cervicitis

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2014101719559N1
Enrollment
130
Registered
2015-03-16
Start date
2014-10-27
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Symptomatic chronic cervicitis. Endocervicitis with or without erosion or ectropion

Interventions

Intervention 1: Intervention: Metronidazol( Alborz Darou pharmaceutical Co.)500 mg given orally twice a day until 10 days. Also cryotherapy in cervix was done with N2o(C 501, EMD Co
Tehran, Iran) until forming ice ball in position for every patient. Intervention 2: Control: Metronidazol( Alborz Darou pharmaceutical Co.)500 mg given orally twice a day until 10 days.
Intervention: Metronidazol( Alborz Darou pharmaceutical Co.)500 mg given orally twice a day until 10 days. Also cryotherapy in cervix was done with N2o(C 501, EMD Co
Tehran, Iran) until forming ice ball in position for every patient.
Control: Metronidazol( Alborz Darou pharmaceutical Co.)500 mg given orally twice a day until 10 days.

Sponsors

Vice chancellor for research, Sabzevar University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
15 Years to 55 Years

Inclusion criteria

Inclusion criteria: Inclusion: Married, Symptoms of chronic cervicitis including: Increase of vaginal discharge, pain during intercourse, vaginal itching and pruritus, age between 15-55 years old Exclusion: Acute vaginal candidiasis, menopause

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Vaginal discharge. Timepoint: One and three months after treatment. Method of measurement: ?Check list.

Secondary

MeasureTime frame
Vaginal itching and pruritus. Timepoint: 1 and 3 months after treatment. Method of measurement: Check list.;Dyspareunia. Timepoint: 1 and 3 months after treatment. Method of measurement: Check list.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactJila Agah

Sabzevar University of Medical Sciences

Jilaagah@yahoo.com+98 51 4423 8104

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026